Found 1 Presentation For Request "447p"
447P - Efficacy and safety of trastuzumab with or without a tyrosine kinase inhibitor for HER2-positive breast cancer: A systematic review and meta-analysis
- Lixi Li (Beijing, China)
Abstract
Background
This study aimed to explore whether the combination of trastuzumab and small molecule tyrosine kinase inhibitor (TKI) can further improve the efficacy of HER2-positive breast cancer without adding additional adverse events.
Methods
PubMed, Embase, Cochrane, and Web of Science were systematically searched for relevant articles from inception until Nov 2022. Overall survival (OS) and progression-free survival (PFS) were the primary outcomes. Subgroup analyses were performed based on disease status and TKI types.
Results
A total of 10,623 patients from 16 studies were included in this meta-analysis. Trastuzumab combined with TKI dual-target blockade showed significant improvement in PFS and OS compared with trastuzumab single-targeted therapy. A random-effects model was applied and the pooled HR was 0.52 (95% CI: 0.41–0.66,
Subgroup analysis for the OS and PFS
Subgroup OS PFS No. of patients Pooled HR (95% CI) No. of patients Pooled HR (95% CI) 5,660 0.77(0.67–0.88) <0.001 1,439 0.52(0.41–0.66) <0.001 tucatinib+trastuzumab 612 0.73(0.59-0.90) 0.003 612 0.57(0.47-0.70) <0.001 lapatinib+trastuzumab 5,048 0.78(0.64-0.96) 0.022 237 0.62(0.44-0.88) <0.001 pyrotinib+trastuzumab - - - 590 0.41(0.32-0.53) <0.001
Conclusions
In summary, combining TKI with trastuzumab confers a significant improvement in clinical outcomes with tolerable toxicity for individuals with HER2-positive breast cancer, especially in advanced settings. The different efficacies of TKIs combined with trastuzumab may be related to the mechanism of action of the different TKIs.
Legal entity responsible for the study
L. Li.
Funding
National Key Research and Development Program of China (2021YFF1201300); CAMS Innovation Fund for Medical Sciences (2021-I2M-1-014); Medical Oncology Key Foundation of Cancer Hospital Chinese Academy of Medical Sciences (CICAMS-MOCP2022007); Cultivation project of Medical Oncology Key Foundation of Cancer Hospital Chinese Academy of Medical Sciences (CICAMS-MOCP2022007).
Disclosure
All authors have declared no conflicts of interest.